sharma, AnjaliMaksane, ShaliniDas, JhumaYadav, DharamveerTomo, SojitSharma, RajeevKumar, SudhirCheirmaraj, KPai, VidyaParab, Kalpana2023-08-092023-08-092022-06sharma Anjali, Maksane Shalini, Das Jhuma, Yadav Dharamveer, Tomo Sojit, Sharma Rajeev, Kumar Sudhir, Cheirmaraj K, Pai Vidya, Parab Kalpana. Carcinoembryonic antigen (CEA) and other surrogate inflammatory biomarkers in COVID-19. Indian Journal of Biochemistry & Biophysics. 2022 Jun; 59(6): 667-6740019-51890975-1009http://imsear.searo.who.int/handle/123456789/221548It has been two years since the global outbreak of the highly contagious and deadly corona virus disease (COVID-19) caused by SARS-CoV-2 first emerged in China. Since then, various diagnostic, prognostic and treatment strategies undertaken to address the pandemic have been dynamically evolving. Predictive and prognostic role of various biomarkers in COVID-19 has been a subject of intense exploration. We aimed to determine the association of Carcinoembryonic antigen (CEA) and various surrogate inflammatory biomarkers with the severity of COVID-19 disease. This retrospective cohort study was carried out on 98 patients admitted in Jaypee Hospital, Noida with COVID-19 disease. Information regarding demographics, laboratory parameters and clinical history was collected from Hospital Information System. Serum levels of CEA and other biomarkers such as Neutrophil-lymphocyte ratio (NLR), C-reactive protein (CRP), Interleukin-6 (IL-6), Ferritin, and Procalcitonin (PCT) were assessed. Correlation analyses were performed between the parameters and acute respiratory distress syndrome (ARDS) stages. Logistic regression and ROC curve analysis were performed to assess the various parameters for distinguishing COVID-19 patients requiring ICU admission. Mean hospital stay, NLR, CEA, IL-6, CRP, Ferritin (P< 0.0001) and PCT (P =0.01) were significantly higher in ICU patients when compared to general ward patients. NLR, median serum CEA, IL-6, and CRP levels were significantly higher in non-survivor compared to the survivors (P< 0.0001, 0.0341 and 0.0092). CEA correlated well with disease severity based upon ARDS classification and was a better marker to differentiate patient according to ARDS stages (ARDS 0 vs 2 P= 0.0006; 0 vs 3 P< 0.0001; ARDS 1 vs 2 P= 0.0183; 1 vs 3 P=0.0006). The area under the Receiver operating characteristic (ROC) curve for CEA was 0.7467 (95% CI- 0.64885- 0.84459) which revealed the potential of CEA as a biomarker to distinguish COVID-19 patients requiring ICU admission. CEA can be used to predict the severity of COVID-19 associated ARDS as well as patients requiring ICU admission. Along with routine inflammatory biomarkers (NLR, CRP, IL-6, PCT, and ferritin), CEA should be used for early identification of critical COVID-19 positive patients and for assessing prognosis.Acute respiratory distress syndromeBiochemical parametersCEAInflammatory markersJournal ArticleIndiaDepartment of Biochemistry, Jaypee Hospital, Noida-201 304, Uttar Pradesh, IndiaDepartment of Biochemistry, Seth G.S. Medical College and K.E.M Hospital, Parel, Mumbai- 400 012, Maharashtra, IndiaConsultant, Department of Biochemistry, Core diagnostics, Gurugram- 122 016, Haryana, IndiaDepartment of Biochemistry, AIIMS, Jodhpur- 342 005, Rajasthan, IndiaDepartment of Biochemistry, Ortho care Diagnostics, New Delhi-110 015, Delhi, India